Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus PANCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus PANCURONIUM BROMIDE.
FLAXEDIL vs PANCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent